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Abstract Diarrhea treatment with either Lactobacillus GG
(LGG) or smectite as an adjuvant to standard rehydration
therapy has proven efficacy. In countries where both LGG
and smectite are available, concomitant use is frequently
practiced. We investigated whether LGG plus smectite is
superior to LGG alone in the management of children with
acute gastroenteritis (AGE). A double-blind, placebo-
controlled, randomized trial was performed. Children aged
4 to 60 months with AGE received LGG 6×109 colony
forming units/day plus randomly either smectite (3 g) or
placebo as an adjuvant to the standard rehydration therapy.
Of the 88 children randomized, 81 (92 %) were available for
intention-to-treat analysis. The duration of diarrhea in the
LGG/smectite group (n044) compared with the LGG/pla-
cebo group (n037) was similar (P00.43). There were no
significant differences between the study groups for the
secondary outcomes, with three exceptions. On day 4, in
the LGG/placebo group compared to the LGG/smectite
group, there was significantly reduced stool frequency (P0
0.03). While there was a significant (P00.05) difference in
stool consistency on the Bristol Stool Form Scale on day 4,
it was not of clinical relevance. Finally, in the LGG/smectite
group compared to the LGG/placebo group, there was a
significantly shorter duration of intravenous therapy after
randomization (P00.02). No adverse events were observed
in the study groups. Conclusion: LGG plus smectite and
LGG alone are equally effective for treating young children
with AGE. Combined use of the two interventions is not
justified.
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Introduction
It is generally recommended that oral rehydration should be
used as first-line therapy to prevent or treat dehydration in
children with acute gastroenteritis (AGE) [5]. Despite the
proven efficacy of oral rehydration therapy, it still remains
underused [6, 14]. The main reason is that oral rehydration
therapy neither reduces the frequency of bowel movements
and fluid loss nor shortens the duration of illness, which
decreases its acceptance. Effective and inexpensive inter-
ventions that could add to the effect of oral rehydration
therapy are of interest to caregivers and health care
professionals.
The European Society for Paediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) and the European
Society of Paediatric Infectious Diseases (ESPID) recom-
mend that select probiotics with proven clinical efficacy
[e.g., Lactobacillus GG (LGG) or Saccharomyces boular-
dii], administered in appropriate dosages, may be used as an
adjunct to rehydration therapy for the management of AGE
in children [5]. The plausible mechanisms by which they
may exert their effects include activation of direct inhibitors
called bacteriocins, reduction of the luminal pH through
short chain fatty acid production (which also inhibits some
pathogens), competition for nutrients, and immunomodula-
tory activity [1]. Also, according to ESPGHAN/ESPID
guidelines, smectite (also known as diosmectite, dioctahe-
dral smectite), a natural hydrated aluminum magnesium
silicate that binds to digestive mucous [10] and has the
ability to bind endo- and exotoxins, bacteria, and rotavirus
[3], may be considered in the management of AGE. In
experimental models, smectite increased water and
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electrolyte absorption and restored the barrier properties of
human intestinal cell monolayers after exposure to tumor
necrosis factor-α [8]. It also modified the activity of bile
salts and the physical properties of gastric mucus, thereby
counteracting mucolysis induced by bacteria [10].
In countries where both LGG and smectite are available,
their concomitant administration is often practiced with the
intention of further reducing the length and severity of
illness. However, there is uncertainty about the benefits of
concomitant administration of LGG and smectite, while
obviously it increases the cost of treatment. The present
study was designed to determine whether LGG plus smec-
tite is superior to LGG alone for the management of children
with AGE.
Methods
The guidelines from the CONSORT statement were followed
for this study [9].
Study design and participants
This was a double-blind, randomized, placebo-controlled trial.
Children aged 4 to 60months with AGE, defined as the passage
of three or more loose or watery stools per day for >1 day but
<5 days, were eligible for inclusion. Exclusion criteria included
diarrhea lasting <1 or >5 days, a recent history of diarrhea
indicated either by parents/guardian or hospital case notes,
underlying chronic gastrointestinal disease, undernutrition
(weight/height ratio below the 5th percentile), systemic infec-
tion, and immune defects or immunosuppressive treatment.
Intervention
If a diagnosis of AGE was made, the child was assessed for
eligibility and written informed consent was obtained. All
patients were initially rehydrated according to the ESPGHAN
and WHO recommendation (oral rehydration or, if not suc-
cessful, intravenous rehydration). Regular feeding was not
interrupted and was carried out after initial rehydration. At
all times, breastfeeding was allowed [5, 17]. Eligible children
received LGG (ATCC 53103) (commercially available as
Dicoflor 30, Vitis Pharma, Poland) at a daily dosage of 6×
109 colony forming units (CFU) in one dose for 7 days plus
randomly either smectite (commercially available as Smecta,
Beaufour, Ipsen, France) or placebo (glucose). Both smectite
and the placebo were administered as an oral dose of 3 g, once
daily, until the diarrhea stopped. LGG was supplied as a
powder in capsules that were opened with the contents ad-
ministered in a small amount of water. The placebo and
smectite were both supplied as a powder and also given in a
small amount of water.While the childrenwere in the hospital,
the study products were administered by hospital staff. If a
child was discharged, the study products were administered by
a parent/caregiver following instructions regarding each prod-
uct’s intake. In both situations, a 3-h interval between the
administration of LGG and the other study products was
recommended. For each child, a diary was kept to record the
frequency and consistency of daily bowel movements, as well
as other symptoms considered to be important or needed for
analysis. The study physician assessed the patient’s diary
during the follow-up visit on day 7. If a child was discharged
during the study period, one of the investigators regularly
contacted the family by phone to ensure adherence.
In all children, at the study entry, stool samples were
collected for microbiological investigations. Standard stool
cultures were used to screen for bacteria (Salmonella, Shi-
gella, Escherichia coli). The presence of rotavirus and en-
teric adenovirus types 40/41 was determined using an
immunochromatographic technique (VIKIA Rota-Adeno,
bioMérieux, Marcy l’Etoile, France) according to the
instructions of the manufacturer.
Outcomes
The primary outcome measure was the duration of diarrhea,
defined as the time from randomization until the last diar-
rheal stool, or as at least 12 h with no stool. The secondary
outcome measures included stool frequency, consistency of
stools determined using the seven-point Bristol Stool Form
Scale [7] (1 for hard lumps to 7 for watery stools—for
details, see Table 1), need for antibiotic therapy (yes/no),
vomiting (yes/no; how many times), diarrhea recurrence,
tolerance of the study products, need for hospitalization
(yes/no, how long), need for unscheduled intravenous rehy-
dration therapy (yes/no, how long), and adverse events.
Sample size
To show a difference of 24 h in duration of diarrhea with α0
0.05 and 80 % power (unpaired Student’s t test), and assum-
ing a 20 % withdrawal rate, a total of 88 participants were
needed. Sample size calculations were performed using
StatsDirect (version 2.5.6; 2006-04-15 StatsDirect statistical
Table 1 Bristol Stool Form Scale [7]
Type 1 Separate hard lumps, like nuts (hard to pass)
Type 2 Sausage-shaped but lumpy
Type 3 Like a sausage but with cracks on the surface
Type 4 Like a sausage or snake, smooth and soft
Type 5 Soft blobs with clear-cut edges
Type 6 Fluffy pieces with ragged edges, a mushy stool
Type 7 Watery, no solid pieces. Entirely liquid
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software. http://www.statsdirect.com. England: StatsDirect
Ltd. 2006).
Randomization and blinding
Block randomization, with a block size of 8, was done with
a computer-generated random number list prepared by an
investigator (HS) with no clinical involvement in the trial.
The list was concealed from the clinicians enrolling patients
and assessing end-points (MPL, MU), as well as from the
parents, until the end of the study. The study products were
prepared centrally in identical packages by the hospital
pharmacy at the Medical University of Warsaw by indepen-
dent personnel not involved in the conduct of the trial.
Statistical methods
The two-tailed Student’s t test was used for comparison of
means of variables approximating a normal distribution. For
non-normally distributed variables, the Mann–Whitney U
test was used. The χ2 test or Fisher exact test, as
appropriate, was used for comparisons of proportions.
The differences between the study groups were consid-
ered significant when the P value was <0.05. All anal-
yses were conducted on an available case basis,
including all participants in the groups to which they
were randomized for whom outcomes were available.




Figure 1 is a flow diagram showing the subjects’ progres-
sion through the study. Of the 88 children who underwent
randomization, 44 were assigned to the experimental group
(LGG/smectite) and 44 were assigned to the control group
(LGG/placebo). Seven children in the control group
Assessed for eligibility 
n=108
Allocated to the experimental 
group (LGG+smectite) n=44
Received allocated intervention 
(n=44)
Allocated to the control group 
(LGG+placebo) n=44
Received allocated intervention 
(n=44)
Discontinued intervention and lost 
to follow-up (n=0)
Analyzed n=44 Analyzed n=37







Fig. 1 Flowchart of subjects
participating in the study
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discontinued the study and eventually were lost to follow-
up. A total of 81 (92 %) children were included in the
analysis.
Recruitment
Participants were recruited from among patients of the pe-
diatric hospital of The Medical University of Warsaw,
Poland, between August 2010 and June 2012.
Baseline data
Baseline demographic and clinical characteristics did not
differ between the two groups and are presented in Table 2.
Outcomes
The outcome measures are summarized in Table 3 and in
Figs. 2 and 3. The duration of diarrhea (the primary out-
come) was similar in the LGG/smectite and LGG/placebo
groups (P00.43). There were no significant differences
between the study groups for the secondary outcomes, with
three exceptions. On day 4, there was reduced stool
frequency in the LGG/placebo group compared with the
LGG/smectite group (P00.03). Also, stool consistency dif-
fered between the groups on day 4. The consistency of
stools was harder in the LGG/placebo compared with the
LGG/smectite group. However, stools with scores of 3, 4,
and 5 on the Bristol Stool Form Scale are referred to as
stools of normal consistency. No significant differences in
stool consistency between groups were observed on any
other day. While there was no significant difference in the
need for intravenous rehydration between the groups, there
was a difference in its duration. In the LGG/smectite group
compared with the LGG/placebo group, there was a signif-
icantly shorter duration of intravenous therapy after random-




Our double-blind, randomized, placebo-controlled study
showed that LGG plus smectite seems to be equally effec-
tive to LGG alone for treating children with AGE. There
were no significant differences between the study groups for
the secondary outcomes, with three exceptions. In the LGG/
placebo group compared to the LGG/smectite group, there
was significantly reduced stool frequency but only on day 4.
While there was a difference between groups in stool con-
sistency, it was not of clinical relevance; this is because
stools with scores of 3, 4, and 5 on the Bristol Stool Form
Scale are referred to as stools of normal consistency. If
unscheduled intravenous rehydration was needed, there
was a significantly shorter duration of intravenous therapy
in the LGG/smectite group compared with the LGG alone
group.
Several factors could explain why the addition of smec-
tite to LGG did not provide any additional benefit over
treatment with LGG alone. The first factor is the mechanism
of action of smectite, including the absorption of bacteria
[3]. While theoretically smectite is directed towards patho-
genic bacteria, one may not exclude the possibility that it
also is directed towards potentially beneficial bacteria such
as LGG. However, in our trial, this explanation seems less
likely, as efforts were made to administer LGG and the other
study products in at least 3-h intervals. A second factor that
may explain the lack of an additional benefit with smectite is
that it may not have been administered at a sufficient dos-
age. We chose a daily dose of 3 g, as recommended by the
manufacturer for children up to 1 year of age. In previous
studies, the daily dose typically ranged from 3 to 6 g
(depending on the age of the children) [13]; however, no
clear dose–effect response has been described. Considering





Male/female (n) 21/23 29/15
Age, months—median (range) 17.5 (10–22.5) 18 (11–30)
Weight, kg—median (range) 10 (9–12) 11 (10–14)
Inpatients/outpatients 34/10 34/10
Vomiting, n (%) 29 (66) 34 (77)
Vomit, episodes per day—median
(range)
2.5 (0–5.25) 2 (1–4)
Dehydration, n (%)
0–3 % 35 (79.5 %) 33 (75 %)
3–9 % 9 (20.5 %) 11 (25 %)
Duration of diarrhea before
randomization, days—median
(range)
1 (1–2.5) 2 (1–2.5)
Diarrhea etiology, n (%)
Rotavirus 25 (57) 30 (68)
Adenovirus 1 (2) 3 (7)






1 (2) 1 (2)
Enteropathogenic E. coli 1 (2) –
E. coli extended spectrum
β-lactamases
1 (2) –
Not identified 10 (23) 6 (14)
No data available 4 (9) 5 (11)
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that the mean age of our patients included in the final
analysis was 18.5 months, the dose of 3 g seems sufficient.
For LGG, we chose a daily intake of 6×109CFU, which
exceeds the minimum dose of 109CFU/day suggested in the
literature for therapeutic purposes. It is noteworthy, howev-
er, that the optimal dose and treatment duration of LGG
therapy have not been clearly established.
Comparison with other studies
To our knowledge, this is the first study to assess concom-
itant administration of LGG with smectite. One previously
published randomized controlled trial (RCT) compared ad-
ministration of a mixture of three probiotic strains, i.e.,
Lactobacillus rhamnosus strains E⁄N, Oxy, and Pen (com-
mercially available as Lakcid, Biomed, Poland), plus smec-
tite with the administration of probiotics alone [12]. This
study was carried out in 107 Polish children aged 6 to
36 months with AGE. The authors reported that in the pro-
biotic/smectite group compared with the probiotic alone
group, there was a significantly shorter duration of fluid
stools, shorter duration of intravenous rehydration, shorter
duration of hospitalization, shorter duration of fever >38 °C,
and greater weight gain. However, there are some method-
ological limitations to the study, including unclear allocation
concealment, no blinding, and no intention-to-treat analysis;
this may result in selection, performance, and/or attrition
biases and, eventually, invalidate the results.







Duration of diarrhea after randomization,
days—median (range)
2 (1–3) 2 (1–2) 0.43
Secondary outcomes
Antibiotic therapy, n (%) – – –
Vomiting, n (%) 9 (20.5) 11 (30) 0.48
Vomiting, number—median (range) 0 (0–0) 0 (0–1) 0.56
Diarrhea recurrence, n (%) 3 (7) 3 (8) 0.83
Study product acceptance, n (%) 34 (77) 32 (86) 0.43
Need for hospitalization, n (%) 34 (77) 31 (84) 0.65
Duration of hospitalization after randomization,
days—median (range)
2 (1–3) 2 (1–4) 0.19
Intravenous rehydration therapy, n (%) 23 (52) 25 (68) 0.24
Duration of intravenous therapy after randomization,
days—median (range)






















Fig. 2 Stool frequency, number per day (median, range)
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Conversely, the efficacy of LGG and smectite administered
separately has been studied in a number of RCTs and their
meta-analyses. For LGG, one meta-analysis of eight RCTs,
involving 988 participants, found that compared with controls,
administration of LGG had no effect on the total stool volume.
However, use of LGG was associated with a significant reduc-
tion in diarrhea duration, particularly that of rotaviral etiology
[15]. A positive effect of using LGG for treating acute diarrhea
was also confirmed in a more recent Cochrane review [1].
For smectite, one meta-analysis of data from six RCTs
showed that smectite significantly reduced the duration of
diarrhea compared with placebo. The chance of cure on
intervention day 3 was significantly increased in the smec-
tite versus the control group, with a number needed to treat
of 4 [13]. Two subsequently performed, large, double-blind
RCTs performed in Peru and Malaysia confirmed a reduc-
tion in diarrhea duration and also indicated a stool output
reduction [4]. The most recent open RCT carried out in India
also found that smectite reduced the duration of diarrhea and
prevented a prolonged course [11].
Strengths and limitations of the study
The strengths of this study include adequate randomization
and the use of intention-to-treat analysis, both of which
minimize the risk of bias. Although there was a comprehen-
sive (92 %) follow-up, there were non-significantly more
patients lost to follow-up in the LGG/placebo group com-
pared with the LGG/smectite group (7 versus 0). As parents
did not report the reasons for refusal to continue, there is no
clear explanation for this finding.
Participants in this study were young children only who
typically develop AGE, so the results are applicable to
clinical practice. On the other hand, our results apply pri-
marily to hospitalized children. In principle, the efficacy of
the treatment may be different for various subgroups (e.g.,
inpatients compared with outpatients). Those admitted to the
hospital may be more severely affected, later in the course of
the disease, or may be more dehydrated, and thus, respond
differently to treatment. Evaluation within these subgroups
is warranted.
A potential limitation of our study is the lack of perfect
blinding. As stated earlier, patients received smectite or
placebo in small, identical packages from the hospital phar-
macy. Both were white powders. However, after being dis-
solved in water, they were of different colors that potentially
could have been an issue if the parent/caregiver had had
previous experience with smectite.
To access stool consistency, we used the Bristol Stool Form
Scale, which has not been validated for the youngest children.
While this study was in the final planning stage, the “Amster-
dam” infant stool scale was published for assessing premature
and term infants’ stool consistency (four items), amount (four
items), and color (six items). The scale is more detailed, and it
might be helpful in differentiating between normal and abnor-
mal defecation patterns in infants; however, it has not been
validated for practical and research purposes [2]. Despite the
limitations of the Bristol Stool Form Scale, it offers a more
objective way of assessing stool consistency than just relying
on the perceptions of caregivers.
In our trial, the duration of diarrhea was used as the
primary measure of outcome. Unfortunately, this measure,
alone, is not considered optimal. Quantitative diarrhea cri-
teria are recommended by the World Health Organization
for use in the evaluation of therapeutic agents for the man-





























Fig. 3 Stool consistency score using Bristol Stool Form Scale (median, range)—1 for hard lumps to 7 for watery stools
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caregivers and health care providers to carry out the cum-
bersome stool collection experienced by us when conduct-
ing some previous trials was the main reason for not
including stool output in this study’s protocol.
Conclusion and implications for practice
While everyone agrees that unnecessary medicines should
be avoided in the treatment of children with AGE, never-
theless some agents are commonly used. The findings from
this RCT help optimize the management of AGE through
the discouragement of the use of regimens with no proven
efficacy but additional costs. The results of this double-blind
RCT indicate that adding smectite to LGG as an adjuvant to
standard rehydration therapy in infants and young children
with AGE does not offer additional benefit. If there is a wish
on the part of caregivers or health care professionals for an
adjunct treatment, the use of either LGG or smectite is a
more rational choice and may be considered.
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